Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: A meta-analysis

David G Binion MD1, Edouard Louis MD PhD2, Bas Oldenburg MD PhD3, Parvez Mulani PhD4, Arielle G Bensimon5, Mei Yang PhD4, Jingdong Chao PhD4

OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn's disease (CD) using a meta-analysis of clinical trials.

METHODS: Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost savings during the year following adalimumab initiation.

RESULTS: The four included trials (ACCESS, CARE, CHOICE and EXTEND) represented a total of 1,202 employed adalimumab-treated patients at baseline. Each study followed patients for a minimum of 20 weeks. Pooled estimates (95% CIs) of one-year accumulated work productivity improvements were as follows: –9% (–10% to –7%) for absenteeism; –22% (–26% to –18%) for presenteeism; and –25% (–30% to –20%) for TWPI. Reductions in absenteeism and TWPI translated into per-patient indirect cost savings (95% CI) of $3,856 ($3,183 to $4,529) and $10,964 ($8,833 to $13,096), respectively.

CONCLUSION: Adalimumab provided clinically meaningful improvements in work productivity among patients with moderate to severe CD, which may translate into substantial indirect cost savings from an employer's perspective.

Key Words: Adalimumab; Crohn’s disease; Indirect costs; Work productivity

L’effet de l’adalimumab sur la productivité au travail et les coûts indirects en cas de maladie de Crohn modérée à grave : une méta-analyse

OBJECTIF : Évaluer l’effet de l’adalimumab sur la productivité au travail et les coûts indirects chez les patients atteints de la maladie de Crohn (MC) au moyen d’une méta-analyse d’essais cliniques.

MÉTHODOLOGIE : Les résultats des études provenant de tous les essais cliniques sur l’adalimumab dans le traitement de la MC modérée à grave et qui en évaluaient les résultats sur la productivité au travail. Les résultats du questionnaire sur la productivité au travail et la détérioration de l’activité (absentéisme, présentéisme et détérioration de la productivité totale au travail [DPTT]) ont été tirés des essais sur l’adalimumab. Les méta-analyses ont permis d’évaluer les moyennes groupées et les 95 % IC quant à la réduction accumulée de la détérioration de la productivité au travail en un an grâce à l’adalimumab. Les moyennes groupées ont été multipliées par le salaire annuel moyen national des États-Unis en 2008 (44 101 $) pour évaluer les économies sur les coûts indirects par patient pendant l’année suivant l’amorce de l’adalimumab.

RÉSULTATS : Les quatre essais inclus (ACCESS, CARE, CHOICE et EXTEND) représentaient un total de 1 202 patients employés traités à l’adalimumab en début d’étude. Chaque étude a suivi les patients pendant au moins 20 semaines. Les évaluations groupées (95 % IC) d’améliorations de la productivité au travail accumulées en un an s’établissaient comme suit : 9 % (–10 % à –7 %) pour l’absentéisme, –22% (–26% à –18%) pour le présentéisme et 25 % (–30% à –20 %) pour la DPTT. La réduction de l’absentéisme et de la DPTT se traduisait par des économies sur les coûts indirects par patient (95 % IC) de 3 856 $ (3 183 $ à 4 529 $) et de 10 964 $ (8 833 $ à 13 096 $), respectivement.

CONCLUSION : L’adalimumab assurait des améliorations significatives sur le plan clinique en matière de productivité au travail chez les patients ayant une MC modérée à grave, qui peuvent se traduire par des économies importantes sur les coûts indirects du point de vue de l’employeur.

C rohn’s disease (CD) is a chronic inflammatory bowel disease usually diagnosed during the second or third decade of life (1), and can have a debilitating effect on patients’ ability to work. Indirect costs of work productivity impairment contribute significantly to the economic burden of CD (2-5). In a large, multicentre clinical trial conducted in North America, Europe and Israel (2), 25% of patients with moderate to severe CD reported receiving some form of disability compensation at baseline. A systematic literature review (4) found that indirect costs associated with CD-related work disability accounted for 28% of the total societal cost of CD in the United States (US) and 64% to 69% in Europe.

Analyses of the effects of biological therapies for CD on productivity outcomes are needed given the high indirect cost burden of CD (6). Improvements in work productivity and employment outcomes have been reported in patients with moderate to severe CD who were treated with certolizumab pegol (7). In addition, preliminary data suggest a positive effect of adalimumab treatment on work productivity outcomes (8-11). The objective of the present meta-analytic study of adalimumab clinical trials was to derive a comprehensive estimate of the effect of adalimumab treatment on work productivity in patients with moderate to severe CD and to estimate the associated one-year indirect cost savings from a societal perspective.

METHODS

Clinical trials and data collection

Data were extracted from all registered, global clinical trials of adalimumab in adult patients with moderate to severe CD in which outcomes based on the Work Productivity and Activity Impairment

1Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; 2University of Liège and CHU Liège, Liège, Belgium; 3University Medical Centre, Utrecht, The Netherlands; 4Abbott Laboratories, Abbott Park, Illinois; 5Analysis Group Inc, Boston, Massachusetts, USA

Correspondence: Dr David G Binion, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, PUH, M2, C Wing, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, USA. Telephone 412-648-9115, fax 412-648-9378, e-mail binion@pitt.edu

Received for publication December 17, 2010. Accepted March 28, 2011

©2011 Pulsus Group Inc. All rights reserved
Questionnaire (WPAI) were evaluated. Included trials were also required to feature an adalimumab-treated arm receiving 160 mg/80 mg induction at weeks 0 and 2, and 40 mg every-other-week maintenance dosing and to follow patients for a minimum of four weeks.

A systematic search of the www.ClinicalTrials.gov registry up to December 2010 was conducted using the phrases “adalimumab” and “Crohn’s disease,” as well as a variation of this search using the brand drug name. The review identified 13 completed trials for the treatment of CD. Of these trials, one study evaluating adalimumab therapy among pediatric patients with CD was excluded (ClinicalTrials.gov identifier: NCT00409682). Also excluded were eight clinical trials and open-label extension studies that did not collect WPAI outcomes (ClinicalTrials.gov identifiers: NCT00255407, NCT00449393, NCT1070303, NCT00445432, NCT01857155, NCT00177779, NCT01055300 and NCT00055523). The four remaining trials were eligible for inclusion in the present meta-analysis.

ACCESS (A Multicenter, Open-Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn’s Disease; NCT00427921) (9), CARE (Crohn’s Patients Treated With Adalimumab: Results of a Safety and Efficacy Study; NCT00496171) (10) and CHOICE (Crohn's Disease WHO Failed Prior Infliximab to Collect Safety Data and Efficacy via Patient-Reported Outcome Measures; NCT00338650) (8) were large, phase IIIb, open-label trials. EXTEND (EXTend the Safety and Efficacy of Adalimumab Through ENDoscopic Healing; NCT00423853) (11) was a phase III, randomized, double-blinded, placebo-controlled trial.

Patients enrolled in the four clinical trials were men and women 18 to 75 years of age with CD confirmed by endoscopic or radiological evaluation. In all trials, eligible patients had moderately to severely active CD (Crohn's Disease Activity Index [CDAI] ≥220 and ≤450 in EXTEND; CDAI >220 or Harvey-Bradshaw Index [HBI] ≥7 in ACCESS; HBI ≥7 in CARE; and based on physician assessment in CHOICE) for at least four months before screening. The EXTEND trial also required a confirmed diagnosis of ileocolonic CD within three years before the baseline visit. Patients enrolled in the ACCESS and CARE trials were refractory to optimal conventional therapies such as 5-aminosalicylic acid, corticosteroids and immunosuppressive therapies (azathioprine, 6-mercaptopurine and methotrexate). The CHOICE trial restricted enrollment to patients with failed response to previous treatment with infliximab including primary nonresponders to infliximab and patients who initially responded to infliximab but discontinued treatment due to adverse events or loss of response. All studies permitted concomitant use of corticosteroids or other conventional therapies for CD provided that patients were receiving stable dosages at baseline. Each of the trials was performed at sites in the US, Canada and/or Europe.

Adalimumab dosing regimens were similar across the trials. The adalimumab-treated cohort in each study was given an induction dose of 160 mg at baseline and 80 mg at week 2, followed by a maintenance dose of 40 mg every other week starting at week 4. Patients who did not demonstrate a clinical response or who experienced a disease flare could increase their dosage to 40 mg weekly.

Relevant data were abstracted from each study including mean work productivity outcomes and measures of variance at each study visit (8-11); studies followed patients for 20 weeks (CARE), 24 weeks (ACCESS and CHOICE) or 52 weeks (EXTEND). Average baseline characteristics of the adalimumab-treated cohort from each trial were also obtained.

Outcome measures
Each trial collected patient responses to the WPAI questionnaire, which is a validated, self-administered tool that assesses the impact of disease on patients’ ability to work (12,13). Three WPAI component scores were computed for employed patients: absenteeism (percentage of work hours missed), presenteeism (visual analogue scale [scored from 0 to 10] rating of impairment while working) and total work productivity impairment (TWPI) (absenteeism and presenteeism combined). Improvements

in absenteeism, presenteeism and TWPI from baseline to the mid-year visit (range: week 20 to week 28, owing to differences in reporting intervals across trials) within each adalimumab-treated cohort were assessed.

Statistical analysis
Meta-analyses were conducted in Stata (StataCorp LP, USA) using the metan command (14) to derive pooled estimates and 95% CIs of improvements in absenteeism, presenteeism and TWPI at weeks 4 and 12, and mid-year study visits. Random-effects models were used when statistical heterogeneity was present (ie, P<0.05); otherwise, a fixed-effects model was used. The resulting pooled estimates and standard errors of productivity improvements at week 4, week 12 and mid-year study visits were weighted to derive estimates of patients’ average productivity improvements during the year following adalimumab initiation, with the assumption that patients experienced a constant rate of improvement between the baseline, week 4, week 12 and mid-year visits, and subsequently maintained the same average improvement from the mid-year visit to week 52. Average productivity improvement over one year was calculated as the area under the resulting curve divided by 52 (the number of weeks in a year). Numerically, this area is equivalent to the area under the stepwise curve that would result if it was assumed that the patients maintained their week-0 improvement from weeks 0 to 2, their week-4 improvement from weeks 3 to 8, their week-12 improvement from weeks 9 to 19, and their week-26 improvement from weeks 20 to 52. Accordingly, the weight of each study visit in the calculation of one-year accumulated productivity improvements was 3.8% (ie, 2/52) for week 0, 11.5% (6/52) for week 4, 21.2% (11/52) for week 12 and 63.5% (33/52) for week 26.

Changes in WPAI scores were interpreted based on a minimum clinically important difference of 7% (15). Pooled absenteeism and TWPI improvements were multiplied by the 2008 US national average annual salary ($4,101) (16) to estimate per-patient one-year indirect cost savings associated with adalimumab.

RESULTS
Clinical trial results pooled from ACCESS, CARE, CHOICE and EXTEND represented a total of 1202 employed adalimumab-treated patients at baseline (Table 1). Mean baseline TWPI scores ranged from 49% to 71% across the trials, indicating substantial work productivity impairment at baseline (Table 1). Within the adalimumab-treated cohort from each trial, clinically significant productivity improvements that exceeded the minimum clinically important difference (ie, 7%) were observed at week 4 and were sustained to the end of the trial period, with the exception of absenteeism at week 4 in ACCESS (six-point improvement) and week 8 in CHOICE (six-point improvement).

Figure 1 summarizes results from the meta-analyses of changes in WPAI outcomes at the week 4, week 12 and mid-year study visits. Combining the reported outcomes from all adalimumab-treated cohorts, the pooled estimates of improvements in WPAI scores from baseline to the mid-year visit were −9.20% (95% CI −11.49% to −6.91%) for absenteeism, −23.90% (95% CI −29.76% to −18.05%) for presenteeism, and −26.64% (95% CI −33.73% to −19.56%) for TWPI. Pooled estimates of productivity improvements at week 4 and week 12 were similar in magnitude. Statistical heterogeneity among the included studies was present in meta-analyses of presenteeism and TWPI (P<0.05 at all study visits) but was not found with respect to absenteeism (P>0.20 at all study visits).

Meta-analysis pooled estimates at individual study visits were aggregated into overall estimates of average improvements in productivity scores over one year. Using weighted averages of pooled estimates at week 4, week 12 and mid-year visits, estimated one-year improvements were −8.74% (95% CI −10.27% to −7.22%) for absenteeism, −22.15% (95% CI −26.12% to −18.18%) for presenteeism and −24.86% (95% CI −29.70% to −20.03%) for TWPI (Table 2).
TABLE 1
Characteristics of adalimumab-treated patient cohorts from studies included in the present meta-analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients in adalimumab cohort, n</th>
<th>Employed at baseline, n (%)</th>
<th>Age, years, mean ± SD</th>
<th>Female, n (%)</th>
<th>Crohn’s disease duration, years, mean ± SD</th>
<th>Previous anti-TNF therapy, n (%)</th>
<th>Work productivity scores at week 0*, mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCESS</td>
<td>304</td>
<td>195 (64.1)</td>
<td>37±12</td>
<td>173 (56.9)</td>
<td>12±10</td>
<td>144 (59.0)</td>
<td>162±27</td>
</tr>
<tr>
<td>CARE</td>
<td>945</td>
<td>543 (57.5)</td>
<td>35±11</td>
<td>568 (60.1)</td>
<td>18±8</td>
<td>461 (48.8)</td>
<td>233±34</td>
</tr>
<tr>
<td>CHOICE</td>
<td>673</td>
<td>423 (62.9)</td>
<td>41±13</td>
<td>398 (59.1)</td>
<td>14±10</td>
<td>673 (100.0)</td>
<td>15±25</td>
</tr>
<tr>
<td>EXTEND</td>
<td>64</td>
<td>41 (64.1)</td>
<td>37±12</td>
<td>81 (62.8)</td>
<td>18±8</td>
<td>78 (60.5)</td>
<td>36±36</td>
</tr>
</tbody>
</table>

*Demographics and disease history are described for the full adalimumab cohort from each trial; †Work productivity scores at week 0 were determined for the subset of patients in the adalimumab-treated cohort who were employed at baseline. ACCESS A Multicenter, Open-Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn’s Disease; CARE Crohn’s Patients Treated With Adalimumab: Results of a Safety and Efficacy Study; CHOICE Crohn’s Disease WHO Failed Prior Infliximab to Collect Safety Data and Efficacy via Patient-Reported Outcome Measures; EXTEND EXTend the Safety and Efficacy of Adalimumab Through Endoscopic Healing; TNF Tumour necrosis factor; TWPI Total work productivity impairment

Figure 1) Meta-analysis pooled estimates of work productivity and activity improvements with adalimumab at week 4, week 12 and mid-year study visits. A Absenteeism, B Presenteeism, C Total work productivity impairment (TWPI). The CI for each study is represented by a horizontal line and the point estimate is represented by the centre of a square. The size of the square corresponds to the weight of the study in the meta-analysis. The CIs for pooled estimates are represented by a diamond shape. ACCESS A Multicenter, Open-Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn’s Disease; CARE Crohn’s Patients Treated With Adalimumab: Results of a Safety and Efficacy Study; CHOICE Crohn’s Disease WHO Failed Prior Infliximab to Collect Safety Data and Efficacy via Patient-Reported Outcome Measures; EXTEND EXTend the Safety and Efficacy of Adalimumab Through Endoscopic Healing

TABLE 2
Average work productivity improvements over one year following initiation of adalimumab therapy

<table>
<thead>
<tr>
<th>Study visit</th>
<th>Weight*</th>
<th>Pooled average productivity improvement according to study visit, mean change, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 0 (baseline)</td>
<td>3.8</td>
<td>0 (-6.77 to 0)</td>
</tr>
<tr>
<td>Week 4</td>
<td>11.5</td>
<td>-8.50 (-10.23 to -6.77)</td>
</tr>
<tr>
<td>Week 12</td>
<td>21.2</td>
<td>-9.09 (-11.10 to -7.09)</td>
</tr>
<tr>
<td>Week 26 (mid-year)</td>
<td>63.5</td>
<td>-9.20 (-11.49 to -6.91)</td>
</tr>
<tr>
<td>Weighted average improvement</td>
<td>494</td>
<td>-8.74 (-10.27 to -7.22)</td>
</tr>
</tbody>
</table>

*The estimate and 95% CI of average accumulated improvement over the one-year period after adalimumab initiation were derived based on a weighted average of the meta-analysis pooled estimates and standard errors of improvements at the week 4, week 12 and mid-year study visits. The weighting scheme was based on the assumption that patients experienced a constant rate of improvement from baseline to week 4, from week 4 to week 12, and from week 12 to the mid-year visit, and subsequently maintained the same average improvement from mid-year until week 52. TWPI Total work productivity impairment
Assuming an average annual salary of $44,101, TWPI improvements translated into an estimated indirect cost savings of $10,964 (95% CI $8,833 to $13,290) per employed patient over the year following adalimumab initiation, owing to reductions in CD-related work loss and productivity impairment. Pooled results for absenteeism indicated expected cost savings of $3,856 (95% CI $3,183 to $4,529) from missed work days alone. The one-year per-patient cost savings from improved productivity while working (presenteeism) was approximated by the difference between TWPI-related and absenteeism-related indirect cost savings ($7,108).

**DISCUSSION**

The present meta-analysis used reported outcomes from four phase III and phase Ib trials to comprehensively evaluate the work productivity benefits of adalimumab maintenance therapy in patients with moderate to severe CD and to quantify the associated indirect cost savings per employed patient from an employer payer’s perspective.

One strength of the current study was the inclusion of outcomes based on the WPAI instrument at multiple time points, which enabled the estimation of changes in both absenteeism- and presenteeism-related productivity impairment with therapy over time. Studies included in the meta-analysis were homogeneous in their findings of clinically meaningful improvements from baseline in all components of the WPAI among employed adalimumab-treated patients. These improvements in productivity were rapid and sustained throughout the follow-up period in each trial. Based on meta-analysis results, we estimated that average improvements in work productivity outcomes during the year following adalimumab initiation were –8.74% for absenteeism, –22.15% for presenteeism and –24.86% for TWPI.

The indirect cost burden of CD takes the form of both greater missed work time and reduced productivity while working. Using national average salary data, estimated reductions in work productivity impairment following adalimumab initiation translated into a one-year per-patient cost savings of $10,964 owing to decreases in absenteeism and presenteeism. Estimated savings from reduced absenteeism alone was $3,856, suggesting that productivity studies that focus only on missed work time are likely to underestimate the impact of CD and its treatment on disease-related work disability.

Previous studies have characterized the high indirect cost burden of CD and established the correlation between disease activity and both direct medical expenditures and indirect work loss costs due to CD (2-5). However, few studies have assessed the impact of therapy on work productivity outcomes. Results from our meta-analysis of WPAI outcomes with adalimumab are consistent with a recent report of significant reductions in absenteeism (~12%), presenteeism (~18%) and TWPI (~21%) associated with 26 weeks of treatment with certolizumab pegol (7). Additional research is needed to examine the productivity benefits of other biological and conventional therapies for CD to better differentiate treatment options in terms of improving occupational functioning and reducing the indirect cost burden of disease.

Limitations of the present study include heterogeneity across the included trials. For purposes of inclusiveness, the meta-analysis pooled data from all completed registered trials of adalimumab in moderate to severe CD with available WPAI outcomes. Although the trials being combined generally used similar study designs, adalimumab dosing regimens and reporting intervals, differences in patient inclusion criteria may help to explain the cross-trial variations in results. For example, the CHOICE trial enrolled patients to have previously experienced treatment failure with infliximab. Including this potentially more-difficult-to-treat patient sample in the meta-analysis was a likely source of heterogeneity, and may have resulted in more conservative estimates of the effect of adalimumab on work productivity. Many patients in the ACCESS, CARE and EXTEND trials also experienced nonresponse to previous infliximab therapy. The mix of antitumour necrosis factor-naïve patients and infliximab nonresponders across the included trials probably reflects a real-world representation of patients with moderate to severe CD.

Furthermore, although the included trials each followed patients for a minimum of 20 weeks, changes in WPAI scores at one year were evaluated only in EXTEND. Owing to the lack of WPAI data at the one-year end point in the other three trials, the one-year cost model assumed that patients maintained the same average WPAI improvements from the mid-year visit until year end. This assumption was supported by the stability of mean WPAI improvements from week 28 to week 52 in the EXTEND trial (11), and by the sustainability of clinical remission and quality-of-life improvements observed in a previous large-sample, one-year trial of adalimumab (17,18). However, additional studies are needed to establish the maintenance of productivity benefits with biological therapy in the longer term.

**CONCLUSION**

Pooled outcomes from four clinical trials demonstrated that adalimumab therapy was associated with significant and clinically meaningful improvements in work productivity for patients with moderate to severe CD. To our knowledge, the present study was the first analysis to show that reductions in work productivity impairment with adalimumab translated into substantial indirect cost savings per employed patient in the year following therapy initiation. The results demonstrate the importance of integrating work productivity outcomes into future economic evaluations of antitumour necrosis factor therapies.

**ACKNOWLEDGEMENTS:** The authors thank Robin L Stromberg, PhD, of Arbor Communications, Inc, Ann Arbor (Michigan, USA) for medical writing and editing services in the preparation of the manuscript. This support was funded by Abbott.

**FINANCIAL SUPPORT:** This study was funded by Abbott Laboratories, Abbott Park, Illinois (USA).

**DISCLOSURE:** Dr Binion has received grants from the National Institutes of Health and UCB Pharma and consulting fees from UCB Pharma. Dr Louis has received research grant support from AstraZeneca and Schering-Plough, speaker fees from Abbott Laboratories, AstraZeneca, Ferring, Schering-Plough and UCB Pharma, and has served as an advisory board member for Abbott Laboratories, Ferring and UCB Pharma. Dr Oldenburg has received grants from Abbott Laboratories, The Netherlands Organisation for Health Research and Development, Schering-Plough, and Tramedico and speaker fees from Ferring Pharmaceuticals. AG Bensimon is an employee of Analysis Group Inc, under contract with Abbott Laboratories for the conduct of this research. Drs Mulani, Yang, and Chao are employees of Abbott Laboratories.

**REFERENCES**


